Skip to content

The effect of platelet-rich plasma on cystitis diseases

The effect of platelet-rich plasma on cystitis diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084068
Enrollment
Unknown
Registered
2024-05-09
Start date
2023-08-07
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder inflammatory diseases

Interventions

the group of intravesical PRP treatment:PRP injection or instillation

Sponsors

The urology department of Beijing Chaoyang Hospital affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 18 to 75 years old, regardless of gender 2.Patients with symptoms of frequent urination, urgency, painful urination, or bladder pain 3.After routine treatment (behavioral therapy, oral medication, bladder infusion, etc.), the effect is poor (GRA score = 4 after treatment) 4.The patient or its legal representative has signed a written informed consent form

Exclusion criteria

Exclusion criteria: 1 Patients with hunner's lesions confirmed by cystoscopy 2. Uncontrolled acute urinary tract infection 3. Bladder outlet obstruction and urethral stricture caused by various reasons 4. Patients with a residual urine volume of> 250ml 5. Neurogenic bladder 6. Benign and malignant tumors 7. Patients with contraindications to catheterization during treatment 8. Uterine, cervical, vaginal or urethral cancer 9. Infectious diseases of the urinary and reproductive systems 10. Contraindications to catheterization during treatment 11. Abnormal decrease in platelets and other abnormalities in the blood system 12. Patients with abnormal laboratory test results during screening, including ALT>3 x upper limit of normal range, AST>3 x upper limit of normal range, and abnormal serum creatinine levels>2 x upper limit of normal range 13. Pregnant, lactating, and pre pregnancy women 14. Suffering from severe cardiovascular and pulmonary diseases, such as congestive heart failure, uncontrolled hypertension, etc., unable to receive regular follow-up 15. Patients with any other serious illness that the researcher deems unsuitable to participate in the trial

Design outcomes

Primary

MeasureTime frame
General reaction assessment;

Secondary

MeasureTime frame
Urinary diary;Urodynamic test;O'leary-sant score;Pain visual analogue scale score,VAS;Quality of Life score,QOL;Pelvic pain and urgency,frequency score,PUF;

Countries

China

Contacts

Public ContactZhang Peng

Beijing Chaoyang Hospital affiliated to Capital Medical University

seabottlezp@126.com+86 136 1104 6169

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026